AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3570862
Drug: 650 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 micrograms daily vitamin A supplement
Trial: 2568777
Drug: 0.75 ml
RxNorm normalized name: ethanol 0.75 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml iopromide/kg body weight
Trial: 2568777
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml iopromide/kg body weight
Trial: 2568777
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml iopromide/kg body weight
Trial: 2568777
Drug: 2.0 ml
RxNorm normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 ml iopromide/kg body weight
Trial: 18159577
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine administration
Trial: 23833309
Drug: Temozolomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (200 mg/m(2)/d) plus cisplatin (75 mg/m(2))
Trial: 23833309
Drug: High-dose IFN-α2b
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN-α2b (HDI)
Trial: 16755435
Drug: MBO model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBO model of treatment (experimental group U[+])
Trial: 16755435
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical treatment (control group K[+])
Trial: 10474470
Drug: Topical 60%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 60% DMSO applied before each filling session
Trial: 8627841
Drug: Followed without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Followed without any treatment
Trial: 1763406
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (7.5 Gy point A dose)
Trial: 1763406
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (6 Gy point A dose)
Trial: 3539037
Drug: Gold therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold therapy
Trial: 28394361
Drug: Walnut oil
RxNorm normalized name: Walnut oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut oil (15 cc daily for 90 days)
Trial: 21704493
Drug: Sham (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham (24 mg)
Trial: 16547328
Drug: Topical ciclosporin
RxNorm normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical ciclosporin A 0.05%
Trial: 14723265
Drug: Conventional antiepileptic
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antiepileptic agents (phenytoin, phenobarbital, carbamazepine, valproic acid)
Trial: 11232180
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy for severe acute alcoholic hepatitis
Trial: 1597912
Drug: Betacarotene as
RxNorm normalized name: betacarotene
DrugBank: Beta carotene (DB06755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betacarotene as a possible skin cancer preventive agent
Trial: 6689670
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture (L‐phenylalanine, L‐tryptophan) infused intraduodenally at increasing rates (0.2, 0.8, and 3.2 ml X min‐1)
Trial: 6689670
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infused into the intestine at increasing rates (0.2, 0.8, and 3.2 ml X min‐1)
Trial: 6689670
Drug: Mannitol solutions
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol solutions of increasing osmolality (370, 520, and 700 mosmol X kg‐1) infused into the duodenum at 0.2 ml X min‐1
Trial: 6689670
Drug: Atropine infusion
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine infusion (20 micrograms X kg‐1 X h‐1)
Trial: 31483549
Drug: Proactive outreach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive outreach intervention (mailed invitation and telephone calls, free cessation treatment including nicotine replacement therapy and intensive telephone counseling)
Trial: 30004139
Drug: MOUTh (Managing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOUTh (Managing Oral Hygiene Using Threat Reduction)
Trial: 25414155
Drug: Liraglutide (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (0.6 mg single dose, titrated to 1.8 mg after 21 days)
Trial: 9424967
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment (Group I)
Trial: 9424967
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg/kg orally (Group II)
Trial: 8462805
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate (4 g per day intravenously for 7 days)
Trial: 30238574
Drug: Intravenous acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acetazolamide at a dose of 500 mg once daily
Trial: 26504153
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (1000 mg) plus prednisone (5 mg)
Trial: 26504153
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (1000 mg) plus exemestane (25 mg)
Trial: 26098476
Drug: n-3 LCPUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 LCPUFA (1.2 g EPA/DHA/day), n=85
Trial: 18270575
Drug: HAMS‐ORS (hypo‐osmolar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAMS‐ORS (hypo‐osmolar ORS with amylase resistant high amylose maize starch 50g/L)
Trial: 15743422
Drug: Emdogain Gel
RxNorm normalized name: Memogain
DrugBank: Benzgalantamine (DB19353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emdogain Gel (EMDgel)
Trial: 14692305
Drug: Tibolone 5
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 5 mg/day
Trial: 14692305
Drug: ECE/MPA (equine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECE/MPA (equine conjugated estrogens 0.625 mg + medroxyprogesterone acetate 2.5 mg/day)
Trial: 10820349
Drug: 1% 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% 5-aminolevulinic acid (5-ALA) topical application after 60-90 minutes
Trial: 781882
Drug: Penicillin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (20 mega-units daily)
Trial: 30407276
Drug: ABT (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT (135 mL of RBC)
Trial: 30407276
Drug: ABT (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT (combined 135 mL and 235 mL of RBC)
Trial: 28623895
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise therapy (Ex group: 18 subjects) - brisk walking for 30 min per day for 12 months
Trial: 28623895
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C group: 18 subjects) - no exercise therapy guidance, only recorded daily steps
Trial: 25631224
Drug: Monthly regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly regular didactic lecture (Group 2)
Trial: 25631224
Drug: Monthly interactive
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly interactive education workshop (Group 3)
Trial: 16634995
Drug: Fosinopril 20
RxNorm normalized name: fosinopril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 20 mg daily
Trial: 10962547
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methylprednisolone (HD MP)
Trial: 9169953
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day beta-carotene in enteral feeding
Trial: 3992070
Drug: Hay fever
RxNorm normalized name: Hay-Crom Hay Fever
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hay fever treatments (specific treatments not detailed)
Trial: 29265566
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ropivacaine 0.2%
Trial: 26067286
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical treatment plus respiratory physiotherapy for 3 weeks
Trial: 12386351
Drug: Uterine balloon
RxNorm normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uterine balloon therapy (UBT)
Trial: 9918905
Drug: Tauroursodeoxycholate (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tauroursodeoxycholate (750 mg/d for 2 months)
Trial: 9918905
Drug: Ursodeoxycholate (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholate (750 mg/d for 2 months)
Trial: 1859038
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate in saline (AS/S) nasal spray
Trial: 25211927
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy including local negative pressure and laser illumination (LLNP)
Trial: 25211927
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with LLNP
Trial: 25211927
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LLNP with PDE5 inhibitors
Trial: 30442259
Drug: Post-therapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-therapy
Trial: 9925136
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus BG2FO4, ingested twice per day for 7 days
Trial: 8583783
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion (48 pmol/kg/min for 15 min)
Trial: 2197347
Drug: Intravenous penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous penicillin
Trial: 510213
Drug: Prazosin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (20 mg/d)
Trial: 27712970
Drug: Statistical model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical model for protamine titration
Trial: 27712970
Drug: Fixed protamine‐heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed protamine‐heparin dose ratio (1:1)
Trial: 14981605
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/d orally)
Trial: 11180005
Drug: Suberythemal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suberythemal dose of whole body irradiation from ultraviolet-A-emitting fluorescent tubes
Trial: 9589815
Drug: Foscarnet (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet (four doses)
Trial: 9589815
Drug: Zalcitabine (five
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalcitabine (five doses)
Trial: 9589815
Drug: Concomitant foscarnet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant foscarnet (four doses) and zalcitabine (six doses)
Trial: 7920609
Drug: Pulse cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse cyclophosphamide (0.5‐1.0 g/m2 body surface area) for 4 months, followed by bimonthly doses for 4 months and quarterly doses for 6 months
Trial: 7920609
Drug: Pulse methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulse methylprednisolone (10‐20 mg/kg weight) initially for 3 consecutive days and thereafter in the same intervals as cyclophosphamide
Trial: 23994192
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS (2mA, 30-min, 10-daily sessions and two additional fortnight sessions)
Trial: 23731168
Drug: Silodosin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin (8 mg/day, n=53)
Trial: 23731168
Drug: Naftopidil (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftopidil (75 mg/day, n=44)
Trial: 16316872
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (200 to 1600 microg/d via pressurized metered-dose inhaler)
Trial: 1929311
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg) once daily for 3 days
Trial: 1929311
Drug: Trimethoprim-sulfamethoxazole (160:800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (160:800 mg) twice daily for 7 days
Trial: 6357014
Drug: Ethanol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (1.5 ml/kg, p.o.)
Trial: 30579860
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bleaching treatment, G1 and G4)
Trial: 28176424
Drug: PAP-guided HF
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Hyco-pap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP-guided HF therapy using the CardioMEMS™ HF system
Trial: 28176424
Drug: PAP-guided HF
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Hyco-pap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP-guided HF therapy using the CardioMEMS™ HF system with estimated staff time included
Trial: 15372416
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid (IVAA) 100 mg after each dialysis session
Trial: 11472293
Drug: Epidural washout
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural washout with twice the volume of 2% mepivacaine (group 2x)
Trial: 7851275
Drug: bezafibrate 400
RxNorm normalized name: bezafibrate 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate 400 mg/day for 4 weeks
Trial: 27014755
Drug: Coffee +
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee + polyethylene glycol + ascorbic acid (750 mL, twice)
Trial: 27014755
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol + ascorbic acid (1-L, twice)
Trial: 18095148
Drug: rhuEpo targeting
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuEpo targeting at Hb >= 13.0 g/dL
Trial: 26557787
Drug: Sleep restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep restriction therapy
Trial: 9847656
Drug: Preemptive lumbar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preemptive lumbar epidural morphine (2 to 4 mg during anesthetic induction)
Trial: 9847656
Drug: Postincisional lumbar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postincisional lumbar epidural morphine (2 to 4 mg upon excision of tissue)
Trial: 7859638
Drug: Gm phenotype
RxNorm normalized name: Proliferation arrested myelomonocytic leukemic cell line-derived cells with a mature dendritic cell phenotype
DrugBank: DCP-001 (DB17423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gm phenotype of g and gft
Trial: 29068592
Drug: Crocin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocin (30 mg per day for 8 weeks)
Trial: 8853725
Drug: Recreational drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational drug use
Trial: 8236402
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg for 30 days
Trial: 8236402
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg for 15 days
Trial: 8236402
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg for 30 days
Trial: 8236402
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg for 30 days and 20 mg/kg for 15 days
Trial: 3122247
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg oral dose)
Trial: 3122247
Drug: Cocaine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (0.2 mg/kg IV injection)
Trial: 28855345
Drug: Intra-arterial treatment
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial treatment (IAT) plus usual care
Trial: 27501767
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus paclitaxel (bevacizumab 10 mg/kg on days 1 and 15 plus paclitaxel 90 mg/m² on days 1, 8, and 15 every 4 weeks)
Trial: 27501767
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus capecitabine (bevacizumab 15 mg/kg on day 1 plus capecitabine 1000 mg/m² twice daily on days 1-14 every 3 weeks)
Trial: 24477043
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training (PRT) combined with a protein-enriched diet facilitated through lean red meat (∼160 g cooked, 6 days/week)
Trial: 18697376
Drug: Diclofenac rectal
RxNorm normalized name: diclofenac Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac rectal suppositories (50 mg, two tablets)
Trial: 18697376
Drug: Placebo rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rectal suppositories (two look-alike tablets)
Trial: 15041587
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral dextromethorphan 30 mg
Trial: 11735011
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin 400 mg and metronidazole 500 mg
Trial: 11735011
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous prophylaxis
Trial: 9428917
Drug: CAF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF (cyclophosphamide 600 mg/m2 i.v., doxorubicin 50 mg/m2 i.v., fluorouracil 600 mg/m2 i.v.)
Trial: 9428917
Drug: DES-CAF (DES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES-CAF (DES 1 mg orally days 1-3, CAF on day 4)
Trial: 30673725
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg/day) for 20 consecutive days
Trial: 26588214
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text message reminders
Trial: 24506498
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa once monthly (QM)
Trial: 16996583
Drug: Tegafur‐Uracil 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegafur‐Uracil 225 mg/m(2)/day orally, 5 days a week and carboplatin 100 mg/m(2) IV weekly on day 1 concurrent with standard radiotherapy (Group A)
Trial: 16996583
Drug: Carboplatin alone
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin alone concurrent with standard radiotherapy (Group B)
Trial: 15498381
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy and embolization via the anterior branches of the bilateral internal iliac arteries
Trial: 15498381
Drug: Adjuvant platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant platinum-based combination chemotherapy (control)
Trial: 3107378
Drug: Citrate as
RxNorm normalized name: orphenadrine citrate 25 mg / aspirin 385 mg / caffeine 30 mg ORAL TABLET [Orphenadrine Citrate Aspirin Caffeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate as the sole anticoagulant for periods of 2 months
Trial: 3107378
Drug: Heparin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin as an anticoagulant
Trial: 31188694
Drug: CHO (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (1.2 g CHO·kg body mass‐1)
Trial: 28197932
Drug: Triptorelin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 0.2 mg
Trial: 28197932
Drug: Triptorelin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 0.3 mg
Trial: 28197932
Drug: Triptorelin 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 0.4 mg